Purpose Imatinib often causes gastric upset resulting in frequent co-administration of an antacid. Elevated gastric pH, delayed gastric emptying, or introduction of Mg 2+ /Al 3+ could potentially change imatinib absorption, thereby aVecting the therapeutic eVectiveness of imatinib. Indeed, antacid co-administration with dasatinib does result in a twofold decrease in dasatinib absorption. We aimed to deWne the eVect of antacid on the pharmacokinetics of imatinib.
Introduction
Imatinib mesylate (Gleevec ® , Glivec ® ), a potent inhibitor of Bcr-Abl and c-Kit tyrosine kinases, is widely used to treat Philadelphia chromosome-positive leukemias and gastrointestinal stromal tumors [4] [5] [6] . Imatinib is associated with dyspepsia (18%) and nausea (43%) [6] and is therefore frequently administered with an acid-neutralizing antacid. Antacids increase the pH of the stomach content, delay gastric emptying, and introduce Mg 2+ and Al 3+ into the gastrointestinal tract. Each of these perturbations could theoretically decrease imatinib absorption, which normally exceeds 97%. Indeed, antacids are known to be associated with a nearly twofold decrease in dasatinib absorption [1] . Whether, and to what extent, antacids used for imatinibassociated gastrointestinal upset inXuence imatinib pharmacokinetics is unknown.
The purpose of this study was to examine the eVect of antacids containing magnesium and aluminum hydroxide salts on the pharmacokinetics of imatinib in healthy volunteers.
Materials and methods

Subjects
The study was approved by the University of Pittsburgh Institutional Review Board. After providing written informed consent, 12 healthy subjects (6 men, 6 women; 20-51 years) completed the study. Eligible subjects were healthy men or women who were 18 years of age or older and had a body mass index (BMI) <31 kg/m 2 . Exclusion criteria included: pregnancy or breast-feeding; abnormal marrow function; evidence of renal dysfunction (proteinuria, estimated creatinine clearance <80 mL/min); impaired hepatic function (liver enzymes or bilirubin > the upper limit of normal); use of any medications (including over the counter products, herbal products, or mineral supplements) with the exception of a daily multivitamin preparation or oral contraceptives (for women).
Study design
The study had a 2-period, open-label, randomized crossover, Wxed-sequence design, and could detect a 30% diVerence in imatinib AUC with 80% power and a 5% type I error, assuming a within-subject variability of 30% [2] . In one period, subjects received 400 mg imatinib (Gleevec; Novartis Pharmaceuticals Corp, East Hanover, NJ) p.o., and in the other, 20 mL Maximum Strength Maalox ® Max ® Antacid/Anti-gas (Novartis) [1.6 g Al(OH) 3 , 1.6 g Mg(OH) 2 , 160 mg simethicone] was administered 15 min prior to 400 mg imatinib p.o. Imatinib was taken with 200 mL of water. The imatinib doses were separated by a wash-out period of 14 days in 11 patients and 21 days in 1 male patient.
Imatinib pharmacokinetics
Venous blood samples (N = 13 per subject, 6 mL each) were drawn from an indwelling catheter into heparin-containing tubes before and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, and 72 h after imatinib administration. Blood samples were centrifuged at 3,000 £ g for 10 min, and the resulting plasma was aspirated and stored at ¡20°C or colder until analyzed.
Analytical procedures
Plasma concentrations of imatinib and its active N-desmethyl metabolite CGP74588 were determined using a previously described LC-MS method [7] that was developed and validated in our laboratory, after adaptation for use with a new instrument. BrieXy, 0.2 mL plasma samples were mixed in a micro-centrifuge tube with 10 L internal standard solution (5 g/mL imatinib-D 8 ; Novartis) before plasma proteins were precipitated with 1 mL of acetonitrile. Samples were centrifuged for 5 min at 16,000 £ g at room temperature, and the resulting supernatants were evaporated to dryness under a gentle stream of nitrogen at 37°C. 
Pharmacokinetic analysis
The pharmacokinetic parameters of imatinib and CGP74588 were determined by standard non-compartmental methods (WinNonlin Professional 4.1, Pharsight, Mountain View, CA). The maximum concentration (C max ) and time to reach the maximum concentration (t max ) were determined by visual inspection of the plasma concentration versus time curves. The imatinib elimination rate constant (k e ) was obtained using non-linear least-square regression of the terminal concentration versus time data. The imatinib area under the concentration versus time curve (AUC) was calculated by the trapezoidal rule (linear up, log down) with extrapolation to inWnity (AUC 0-1 ) beyond the last sample time (C last ). The percentage of AUC 0-1 extrapolated beyond C last indicates what fraction of the AUC 0-1 is not based on our plasma determinations, but is estimated by extrapolation. Ideally the percentage extrapolated is less than 20%.
Statistical analysis
Calculations were performed using SPSS 15.0 for Windows (SPSS Inc., Chicago, IL). The pharmacokinetic parameter estimates of imatinib and CGP74588 determined in the presence and absence of antacid were compared (after logarithmic transformation) with a two-tailed, paired t test, where a P < 0.05 was considered signiWcant. We also tested for a sequence eVect, to determine if there was a diVerence between the pharmacokinetics during the Wrst and second study visit, unrelated to antacid co-administration. The values for imatinib t max , CGP74588 t max , and CGP74588 half-life, after log transformation, did not follow a normal distribution (signiWcance observed by the KolmogorovSmirnov test for normality). Therefore, the untransformed values for these parameters were analyzed by the two-tailed exact Wilcoxon signed rank test.
We also performed an analysis of bioequivalence by calculating the 90% conWdence intervals of the imatinib AUC ratio and the C max ratio, based on log-transformed data, both of which should fall within the equivalence limits of 80-125% [3] .
Results
Imatinib was well-tolerated by all 12 subjects, each of whom completed the study successfully. There was no sequence eVect, i.e. the pharmacokinetics was not diVerent between the Wrst and second administration of imatinib. The pharmacokinetic parameter estimates for imatinib are shown in Table 1 . The percentage of the AUC extrapolated beyond C last was <5% for imatinib, allowing us to interpret our data with conWdence. Concentration versus time curves of imatinib and CGP74588 in the presence and absence of antacid, respectively, are shown in Fig. 1 .
The primary pharmacokinetic parameter to which this study was powered was imatinib AUC, a measure of the amount of imatinib absorbed. There was no signiWcant diVerence in imatinib plasma AUC after dosing imatinib alone, compared to in the presence of antacid (P = 0.37). The 90% conWdence intervals of the imatinib AUC ratio (mean 1.04, 90% conWdence interval 0.96-1.12) and the C max ratio (mean 1.00, 90% conWdence interval 0.92-1.08), both fall well within the limits set for bioequivalence [3] .
We also examined the eVect of antacids on other pharmacokinetic parameters for imatinib and CGP74588 (Table 1) . We only detected a small diVerence in the AUC and clearance of CGP74588 (approximately 10%; P = 0.03).
Discussion
In conclusion, this study demonstrates that concomitant administration of a Mg 2+ -Al 3+ -based antacid is not associated with meaningful alterations in imatinib absorption. This is in striking contrast to dasatinib, where antacids have been associated with a nearly twofold decrease in dasatinib absorption [1] . The reason for this interaction is not clear, but may be due to limited dissolution of the dasatinib base in an environment with elevated pH, or due to chelation of the abundant Mg 2+ or Al 3+ cations by dasatinib, resulting in unabsorbable complexes. The small diVerence in the AUC Table 1 Mean pharmacokinetic parameter estimates for imatinib and N-desmethyl-imatinib (CGP74588) alone and with co-administration of antacid (N = 12)
The data are expressed as mean (standard deviation) The percentage of the AUC 0-1 extrapolated beyond C last was <5% for imatinib and <35% for CGP74588 and clearance of CGP74588 would not be expected to have any clinical relevance.
